Why CDI

Our Technology

Stem Cells: Limitless and PluripotentPowered by iPSC

Stem cells are early stage, undifferentiated cells that are found in all multicellular organisms. They are unique because they can survive and replicate indefinitely and have the capacity to differentiate into any cell type in the human body (pluripotency). There are two general types of stem cells:

  • Embryonic stem (ES) cells: Derived from early stage embryos
  • Induced pluripotent stem (iPS) cells: Generated from cells obtained from donors such as adult skin or blood

Scientific research and clinical development that are performed using iPS cells avoid the social and political issues associated with ES cells.

Making Induced Pluripotent Stem Cells

The process of generating iPS cells is referred to as reprogramming and involves the directed expression of pluripotency genes in adult cells. CDI has developed and optimized an episomal reprogramming process that utilizes circular DNA vectors to deliver the pluripotency genes. Episomal reprogramming has significant benefits over other reprogramming methods, especially for clinical applications.

Only one simple blood draw is needed to produce a potentially unlimited supply of iPS cells.

Differentiating iPS Cells into Diverse Cell Types

After manufacturing iPS cells, CDI uses proprietary methods to direct the cell differentiation mechanisms that can make industrial quantities of high quality, highly pure differentiated tissue cells, which include cardiomyocytes, neurons, and hepatocytes. Since first being described in 2007 (Takahashi, et al., Yu, et al.), iPS cells and the resulting tissue cells derived from them have been produced from donors representing broad ethnic, genetic, and disease state diversity.

iPS cells enable the production of industrial quantities of differentiated tissues cells.

 

Changing the World of Medicine

In many instances, iPS cell-derived tissue cells can recapitulate relevant donor disease biology in the laboratory, a capability often referred to as “disease-in-a-dish.” This capability has led to new insights into mechanisms that underlie some of the most devastating human diseases, as well as powerful new approaches to disease modeling and drug discovery.  With their advantages, iPS cell-derived tissue cells also provide a critical resource in the development of autologous cell transplantation clinical therapies.

Learn more about drug discovery,  clinical advances, and other human health improvements based on CDI’s iPS cell platform.